XML 69 R56.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaborative Research, Development and License Agreements - Additional Information (Detail) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 8 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Jul. 12, 2018 USD ($) | Feb. 28, 2018 USD ($) Installment | Jan. 31, 2018 USD ($) | Jun. 30, 2016 USD ($) | Mar. 31, 2020 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Sep. 30, 2017 USD ($) | Jun. 30, 2017 USD ($) | Mar. 31, 2017 USD ($) | Jul. 31, 2018 | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | $ 5,318 | $ 1,461 | $ 1,254 | $ 165 | $ 21 | $ 53 | $ 105 | $ 148 |  | $ 8,198 | $ 327 | $ 11,043
Intangible assets, net |  |  |  |  |  |  | 11,717 |  |  |  |  |  |  |  |  | 11,717 |  |
Collaboration Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,386 |  | $ 9,778
Astra Zeneca | Collaboration Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  | $ 9,800 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Merck, Sharp & Dohme Corp. | Sublicense Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate amount payable to acquire intangible assets |  | $ 21,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of installments | Installment |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment upon obligation |  | $ 7,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  | $ 19,800 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets, net |  |  |  |  |  |  | $ 11,700 |  |  |  |  |  |  |  |  | 11,700 |  |
Merck, Sharp & Dohme Corp. | Sublicense Agreement | Scenario, Forecast |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment upon obligation |  |  |  |  | $ 7,000 | $ 7,000 |  |  |  |  |  |  |  |  |  |  |  |
GlaxoSmithKline Biologicals SA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty on net sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13.00% |  |  |
GlaxoSmithKline Biologicals SA | License |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment upon obligation | $ 1,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
GlaxoSmithKline Biologicals SA | Royalty |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties in cost of sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 200 |  |
Coley Pharmaceutical Group, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2018-02 |  |
Amortization of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,500 |  |
Coley Pharmaceutical Group, Inc. | Intangible Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment upon obligation |  |  | $ 2,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Aggregate amount payable to acquire intangible assets. + References No definition available. + Details
Name: | dvax_AggregateAmountPayableToAcquireIntangibleAssets
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Agreement termination period month and year. + References No definition available. + Details
Name: | dvax_AgreementTerminationPeriodMonthAndYear
Namespace Prefix: | dvax_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Intangible assets fully amortized. + References No definition available. + Details
Name: | dvax_IntangibleAssetsFullyAmortized
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of installments. + References No definition available. + Details
Name: | dvax_NumberOfInstallments
Namespace Prefix: | dvax_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty on net sales. + References No definition available. + Details
Name: | dvax_PercentageOfRoyaltyOnNetSales
Namespace Prefix: | dvax_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount before accumulated amortization of intangible assets, excluding goodwill. + References No definition available. + Details
Name: | us-gaap_IntangibleAssetsGrossExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=dvax_CollaborationRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dvax_MerckSharpAndDohmeCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dvax_SublicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dvax_GlaxoSmithKlineBiologicalsSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dvax_ColeyPharmaceuticalGroupIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=dvax_IntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |